Personalis PSNL 深 滬
已收盤 07-02 16:00:00 美东时间
13.62
-0.170
-1.23%
華盛通- 最 高14.24
- 今 開13.97
- 成交量 378.86万股
- 最 低 13.2344
- 昨 收 13.79
- 總市值 14.26亿
- 52周最高 14.24
- 市盈率 靜 --
- 換手率 3.62%
- 52周最低 3.84
- 委 比 -5.88%
- 總股本 1.05亿
- 歷史最高 53.46
- 量 比 0.74
- 振 幅 7.29%
- 歷史最低 0.8906
- 每 手 1
- 風險率 1.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Personalis陷盈利困境仍显现向好信号
本次内容针对美股标的Personalis（股票代码：PSNL.O）展开多维度分析，覆盖股价走势、行业环境、机构观点、基本面、资金流向与交易策略等核心维度。 技...
06-27 11:03
Personalis大涨18% 深陷盈利危机
核心事件：美股公司Personalis（PSNL.O）近期股价录得18.21%涨幅，当前处于剧烈波动状态，多重因素交织下市场对其后续走势存在分歧。 关键行业动态...
06-26 11:09
Personalis在纳斯达克走弱之际突破阻力位
生物科技公司Personalis（股票代码：PSNL）盘中涨幅超10%，交易价格约12.56美元，突破12.53美元的60日高点关键结构性阻力。此次突破发生于纳...
06-25 23:40
Personalis Wins EU Compliance Mark for Cancer Testing Blood Kits, Blood Collection Kits Receive European Diagnostic Mark
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD
06-09 18:06
Personalis blood collection kits win EU CE-IVD mark under IVDR
Personalis blood collection kits win EU CE-IVD mark under IVDR Personalis obtained Class A CE-IVD marking under the EU IVDR for its EDTA blood collection kit and cfDNA blood collection kit. The clearance enables use of the kits at clinical trial sites across the EU and Great Britain, supporting glob
06-09 18:00
Personalis Highlights Cancer-Detection Data Across Multiple Tumor Types
Personalis, Inc. (NASDAQ:PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid
06-02 18:17
Personalis CEO Christopher M. Hall disposes of common shares worth $1,101,800.18
Personalis CEO Christopher M. Hall disposes of common shares worth $1,101,800.18 Personalis CEO Christopher M. Hall sold 100,000 common shares on May 28-29 at a weighted average USD 11.02. Sales followed option exercises at USD 1.61, totaling 100,000 shares over the same two days. Hall’s direct comm
05-30 08:45
Personalis CFO, COO Aaron Tachibana disposes of common shares valued at $449,248.42
Personalis CFO, COO Aaron Tachibana disposes of common shares valued at $449,248.42 Personalis CFO and COO Aaron Tachibana exercised stock options for 38,799 common shares at USD 9.16 on May 29, 2026. He sold 38,799 common shares at a weighted average USD 11.58 in the same transaction set. Directly
05-30 08:27
Personalis to Present New Cancer Detection Data at Major Oncology Conference
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced that six clinical abstracts demonstrating the broad use of its NeXT Personal® test will be presented at the 2026
05-26 18:07
